ImmunoNova: The Evolution of Vitiligo Treatments
What Vitiligo Really Is
Vitiligo is an autoimmune disease: the immune system “targets the wrong cells” and attacks the melanocytes, causing lighter patches on various areas of the body (face, hands, elbows, knees, genitals). It is neither painful nor contagious, but it can have a significant psychological impact. The skin is where the disease manifests itself, not necessarily where it originates.
From a Local Approach to a Systemic Vision: Why a Change Was Needed
Exclusively “local” therapies (only creams or only light therapy) risk extinguishing the fire on the surface without reducing the immune activation that fuels new patches. In our experience and in the scientific literature, topical treatment alone is not enough to prevent progression and recurrence: a pathway capable of rebalancing immunity and promoting safe repigmentation is required.
From the Counterphasic Protocol to ImmunoNova: What Changes
The counterphasic protocol represented an important step in our internal evolution. ImmunoNova represents its clinical advancement: a proprietary protocol integrating five pillars, with periodic monitoring and optimized adherence (a single daily treatment window, usually in the evening).
The 5 Pillars of ImmunoNova
- Clinical Evaluation and VAI
Specialist consultation, Wood’s lamp photography, and calculation of the Vitiligo Activity Index to define disease activity, extent, and therapeutic goals.
- Gut Health and Barrier Function
Medical history assessment and targeted nutrition to address gastrointestinal dysfunctions (leaky gut), which may contribute to a pro-inflammatory state.
- Microbiota and Vitamin D3
Immunoregulatory probiotic strains and Vitamin D3 supplementation with periodic monitoring: modulation of immune response and support for melanogenesis.
- Home-Based NB-UVB Phototherapy
Daily use, in sub-erythemal doses, with certified devices: in our experience, this is the most effective and sustainable long-term option, even for extensive areas.
- Topical Therapies
Immunomodulators during active phases and melanocyte-stimulating agents during quiescent phases, selected according to body area, extent, and tolerability.
The entire pathway is organized into an “evening block” (between dinner and post-dinner hours) to improve adherence and therefore real-life effectiveness.
Evidence and Realistic Expectations
- The face and “fast-response” areas often improve more quickly; hands and distal phalanges require more time and consistency. Every area has clinical importance and should be followed through monitoring and periodic adjustments.
- Adherence is crucial: when adherence is high, the percentage of consultations showing improvement increases significantly in our internal data.
- Timing and outcomes vary according to age, disease duration and activity, affected areas, comorbidities, and individual response.
The Difference in Summary: Counterphasic vs ImmunoNova
- Approach: from the sequential focus of the counterphasic method to an integrated 5-pillar model.
- Clinical target: not only repigmentation, but also reducing immune activation and preventing new patches.
- Adherence: treatment concentrated into a single moment of the day, with follow-ups every 2–4 months.
- Personalization: therapeutic choices modulated according to VAI, affected areas, comorbidities, and patient preferences.
Would you like to understand whether the ImmunoNova protocol for vitiligo may be suitable for you?
Book a consultation or request an evaluation with our team.
Author: Istituto Dermacademy
